Finjan Holdings, Inc.
Finjan Holdings, Inc. (FNJN) related to its sale to CFIP Goldfish Holdings, LLC. Under the terms of the agreement, Finjan shareholders will receive $1.55 in cash for each share of Finjan common stock owned.
Finjan Holdings, Inc. (FNJN) related to its sale to CFIP Goldfish Holdings, LLC. Under the terms of the agreement, Finjan shareholders will receive $1.55 in cash for each share of Finjan common stock owned.
Arya Sciences Acquisition Corp. (ARYA) related to its combination with Immatics B.V., a Netherlands private limited company. Under the terms of the agreement, each outstanding share of Arya common stock, will be automatically exchanged for one share of the newly formed company, Immatics N.V.
Assertio Therapeutics, Inc. (NasdaqGS: ASRT) related to the creation of a combined company between Assertio Therapeutics and Zyla Life Sciences. Under the terms of the agreement, Assertio Therapeutics will issue 2.5 shares to each Zyla stockholder. Assertio Therapeutics stockholders will own 68% and Zyla stockholders will own 32% of the combined company.
Portola Pharmaceuticals, Inc. (PTLA) related to its sale to Alexion Pharmaceuticals, Inc. Under the terms of the agreement, Portola shareholders will receive $18.00 in cash for each share of Portola common stock owned.
Quintana Energy Services Inc. (QES) related to the combination with KLX Energy Services Holdings, Inc. Under the terms of the agreement, each share of Quintana common will be converted into the right to receive 0.4844 shares of KLX Energy common stock. KLX Energy will own 59% and Quintana stockholders will own 41% of the combined … Read more
KLX Energy Services Holdings, Inc. (KLXE) related to the combination with Quintana Energy Services Inc. Under terms of the agreement, KLX Energy will issue 0.4844 shares to each share owned by Quintana stockholder. KLX Energy stockholders will own 59% of the combined company and Quintana stockholders will own 41%.
Stemline Therapeutics, Inc. (STML) related to its sale to Berlin-Chemie AG. Under the terms of the agreement, Stemline shareholders will have the right to receive (i) $11.50 in cash plus (ii) one contingent value right for each share of Stemline common stock owned.
resTORbio, Inc. (TORC) relating to the combination with Adicet Bio, Inc. Under the terms of the agreement, Adicet shareholders are expected to own approximately 75% of the combined company and resTORbio shareholders are expected to own 25%.
Asta Funding, Inc. (ASFI) relating to its sale to Asta Finance Acquisition Inc. Under the terms of the agreement, Asta Funding shareholders shall be entitled to receive $11.47 in cash for each share of Asta Funding common stock owned.
Standard Diversified Inc. (SDI) relating to its sale to Turning Point Brands, Inc (“TPB”). Under the terms of the agreement, each share of SDI Class A and Class B common stock will be converted into the right to receive a ratio of 0.97 of TPB Voting common stock for each share of TPB common stock … Read more